Search

Your search keyword '"Kyriazoglou, Anastasios"' showing total 208 results
Start Over Author "Kyriazoglou, Anastasios"
208 results on '"Kyriazoglou, Anastasios"'

1. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC)

Author

Economopoulou, Panagiota, Spathis, Aris, Kotsantis, Ioannis, Maratou, Eirini, Anastasiou, Maria, Moutafi, Myrto K., Kirkasiadou, Maria, Pantazopoulos, Anastasios, Giannakakou, Maria, Edelstein, Daniel L., Sloane, Hillary, Fredebohm, Johannes, Jones, Frederick S, Kyriazoglou, Anastasios, Gavrielatou, Niki, Foukas, Periklis, Panayiotides, Ioannis, and Psyrri, Amanda

Published
2023
Full Text
View/download PDF

2. Expression of DNA Repair Genes in Ewing Sarcoma

Author

KYRIAZOGLOU, ANASTASIOS, primary, MOUTAFI, MYRTO, additional, ZOGRAFOS, ELENI, additional, KONTELES, VASSILIS, additional, SOFIANIDIS, GEORGIOS, additional, MAHAIRA, LOUISA, additional, PAPAKOSTA, ALEXANDRA, additional, TOURKANTONI, NATALIA, additional, PATERELI, AMALIA, additional, STEFANAKI, KALLIOPI, additional, TZOTZOLA, VASILIKI, additional, MPAKA, MARGARITA, additional, POLYCHRONOPOULOU, SOFIA, additional, DIMITRIADIS, EFTHYMIOS, additional, and KATTAMIS, ANTONIS, additional

Published
2024
Full Text
View/download PDF

3. Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives

Author

Moreno Jose Duran, Papageorgiou Georgios, Gazouli Ioanna, and Kyriazoglou Anastasios

Subjects
ewing sarcoma, chemotherapy, systemic treatment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Ewing sarcoma (ES) is an uncommon malignant neoplasm, mostly affecting young adults and adolescents. Surgical excision, irradiation, and combinations of multiple chemotherapeutic agents are currently used as a multimodal strategy for the treatment of local and oligometastatic disease. Although ES usually responds to the primary treatment, relapsed and primarily refractory disease remains a difficult therapeutic challenge. The growing understanding of cancer biology and the subsequent development of new therapeutic strategies have been put at the service of research in recurrent and refractory ES, generating a great number of ongoing studies with compounds that could find superior clinical outcomes in the years to come. This review gathers the current available information on the treatment and clinical investigation of ES and aims to be a point of support for future research.

Published
2022
Full Text
View/download PDF

6. The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers.

Author

Kokkali, Stefania, Boukovinas, Ioannis, de Bree, Eelco, Koumarianou, Anna, Georgoulias, Vassilis, Kyriazoglou, Anastasios, Tsoukalas, Nikolaos, Memos, Nikolaos, Papanastassiou, John, Stergioula, Anastasia, Tsapakidis, Konstantinos, Loga, Konstantia, Duran-Moreno, Jose, Papanastasopoulos, Panagiotis, Vassos, Nikolaos, Kontogeorgakos, Vasileios, Athanasiadis, Ilias, Mahaira, Luiza, Dimitriadis, Efthymios, and Papachristou, Dionysios J.

Subjects
SARCOMA, GENOMICS, RESEARCH funding, SCIENTIFIC observation, CANCER patients, DESCRIPTIVE statistics, LONGITUDINAL method, RESEARCH, MOLECULAR pathology, SEQUENCE analysis
Abstract

Simple Summary: Sarcomas represent a group of rare tumors consisting of more than 100 different entities. A precise diagnosis is crucial to optimal treatment. In addition, a significant proportion of sarcomas are characterized by a specific genetic abnormality. This study was designed by the Hellenic Group of Sarcoma and Rare Cancers to assess the effect of expert pathology review, coupled with the application of molecular methods to detect genetic abnormalities, on the diagnosis and management of sarcoma patients in Greece. We found that histological diagnosis review by a sarcoma pathologist led to modifications in diagnosis in almost one-third of patients, resulting in modifications in management in 14% of patients. The use of molecular tests led to modifications in diagnosis in 26% of patients, resulting in modifications in management in almost 11% of patients. Our study highlights the importance of expert pathologists, assisted in some cases by molecular methods, in sarcoma diagnosis and treatment. Precise classification of sarcomas is crucial to optimal clinical management. In this prospective, multicenter, observational study within the Hellenic Group of Sarcoma and Rare Cancers (HGSRC), we assessed the effect of expert pathology review, coupled with the application of molecular diagnostics, on the diagnosis and management of sarcoma patients. Newly diagnosed sarcoma patients were addressed by their physicians to one of the two sarcoma pathologists of HGSRC for histopathological diagnostic assessment. RNA next-generation sequencing was performed on all samples using a platform targeting 86 sarcoma gene fusions. Additional molecular methods were performed in the opinion of the expert pathologist. Therefore, the expert pathologist provided a final diagnosis based on the histopathological findings and, when necessary, molecular tests. In total, 128 specimens from 122 patients were assessed. Among the 119 cases in which there was a preliminary diagnosis by a non-sarcoma pathologist, there were 37 modifications in diagnosis (31.1%) by the sarcoma pathologist, resulting in 17 (14.2%) modifications in management. Among the 110 cases in which molecular tests were performed, there were 29 modifications in diagnosis (26.4%) through the genomic results, resulting in 12 (10.9%) modifications in management. Our study confirms that expert pathology review is of utmost importance for optimal sarcoma diagnosis and management and should be assisted by molecular methods in selected cases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy

Author

Liontos, Michalis, Sotiropoulou, Maria, Kaparelou, Maria, Tzannis, Kimon, Tsironis, George, Kyriazoglou, Anastasios, Tsiara, Anna, Zakopoulou, Roubini, Koutsoukos, Konstantinos, Zagouri, Flora, Thomakos, Nikolaos, Haidopoulos, Dimitrios, Rodolakis, Alexandros, Dimopoulos, Meletios A., and Bamias, Aristotelis

Published
2020
Full Text
View/download PDF

8. Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC)

Author

Ntanasis-Stathopoulos Ioannis, Kyriazoglou Anastasios, Dimopoulos Meletios A., and Gavriatopoulou Maria

Subjects
biomarker, therapeutics, cancer, pd-l1, kras, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Treatment personalisation plays a key role in the current management of patients with cancer. Several biomarkers have shown clinical utility and may guide therapeutic decisions. Amongst patients with lung cancer, the level of expression of programmed death ligand 1 (PD-L1) has both prognostic and predictive values in terms of response to the inhibition of programmed cell death protein 1 (PD-1). Depending on the clinical setting, the expression of PD-L1 ≥1% or ≥50% has been associated with improved outcomes amongst patients receiving pembrolizumab. Regarding patients with colorectal carcinoma, mutations in the KRAS oncogene predict the responsiveness to the inhibition of epidermal growth factor receptor (EGFR). Only patients with wild-type KRAS tumours derive benefit from cetuximab and panitumumab in terms of response and survival. In conclusion, future research should aim in the optimisation of the use of biomarker in the clinical practice in order to provide the optimal drug combination to each individual patient.

Published
2020
Full Text
View/download PDF

12. Clinical and biological implications of Hippo pathway dysregulation in sarcomas

Author

Kyriazoglou Anastasios, Zakopoulou Roubini, Zagouri Flora, Bamias Aristotelis, and Dimopoulos Meletios Athanasios

Subjects
sarcomas, hippo pathway, yap, taz, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Sarcomas are mesenchymal malignant tumors with poor prognosis and limited treatment options. Hippo pathway is a recently discovered pathway normally involved in organ development and wound healing. Hippo signaling is often altered in solid tumors. The molecular elements of Hippo signaling include MST1/2 and LATS1/2 kinases which phosphorylate and regulate the activity of YAP and TAZ co-transcriptional activators. Hippo pathway cross-talks with several molecular pathways with known oncogenic function. In sarcomas Hippo signaling plays a pivotal role in tumorigenesis, evolution and resistance in chemotherapy regimens. Targeting Hippo pathway could potentially improve prognosis and outcome of sarcoma patients.

Published
2019
Full Text
View/download PDF

15. Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease

Author

Kyriazoglou Anastasios, Dimitriadis Ioannis, and Bamias Aristotelis

Subjects
renal cell carcinoma, metastatic disease, therapeutic algorithm, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The treatment paradigm in renal cell carcinoma (RCC) is rapidly changing. The incidental finding of small renal tumours combined with the development of novel therapeutic agents targeting the vascular endothelial growth factor (VEGF) or the mammalian target of rapamycin (mTOR) pathways or inhibiting the interaction of the programmed death 1 (PD 1) receptor with its ligand have dramatically improved the prognosis of patients suffering from this malignancy. At the same time, the availability of multiple effective options with similar indications complicates the development and applicability of guidelines in this disease. We conducted a systematic review of the existing guidelines. Our study revealed areas of agreement as well as of discrepancies amongst the published scientific papers included. By critically evaluating these areas, we developed a therapeutic algorithm for RCC. We suggest that this methodology can define the practices of wide applicability and areas of future research.

Published
2017
Full Text
View/download PDF

20. Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis

Author

Andrikopoulou, Angeliki, primary, Zografos, Eleni, additional, Apostolidou, Kleoniki, additional, Kyriazoglou, Anastasios, additional, Papatheodoridi, Alksistis-Maria, additional, Kaparelou, Maria, additional, Koutsoukos, Konstantinos, additional, Liontos, Michalis, additional, Dimopoulos, Meletios-Athanasios, additional, and Zagouri, Flora, additional

Published
2022
Full Text
View/download PDF

21. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm

Author

Bamias, Aristotelis, primary, Zakopoulou, Roubini, additional, Tzannis, Kimon, additional, Sakellakis, Minas, additional, Koutsoukos, Konstantinos, additional, Kyriazoglou, Anastasios, additional, Panagiotou, Aikaterini, additional, Armylagos, Stylianos, additional, Rokas, Konstantinos, additional, Gotzias, Dimitrios, additional, Boulouta, Anna, additional, Bozionelou, Vassiliki, additional, Stravodimos, Konstantinos, additional, Varkarakis, Ioannis, additional, Mavroudis, Dimitrios, additional, and Dimopoulos, Meletios-Athanasios, additional

Published
2022
Full Text
View/download PDF

22. Myxoid spindle cell sarcoma with ETV6‐NTRK3 fusion

Author

Kyriazoglou, Anastasios, primary, Dimitriadis, Efhtymios, additional, Mahaira, Luiza, additional, Kotsantis, John, additional, Kouloulias, Vasileios, additional, Kontogeorgakos, Vasileios, additional, Psyrri, Amanda, additional, and Agrogiannis, Georgios, additional

Published
2022
Full Text
View/download PDF

23. Abstract 3882: Translating genotype to immunophenotype in HRAS mutated head and neck squamous cell carcinoma (HNSCC) to identify effective Tipifarnib partners for optimal patient outcomes

Author

Psyrri, Amanda, primary, Anastasiou, Miriam, additional, Spathis, Aris, additional, Doumas, Stergios, additional, Economopoulou, Panagiota, additional, Kotsantis, Ioannis, additional, Pantazopoulos, Anastasios, additional, Kyriazoglou, Anastasios, additional, Kavourakis, George, additional, Rampias, Theodoros, additional, and Foukas, Periklis, additional

Published
2022
Full Text
View/download PDF

24. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.

Author

Bamias, Aristotelis, Zakopoulou, Roubini, Tzannis, Kimon, Sakellakis, Minas, Koutsoukos, Konstantinos, Kyriazoglou, Anastasios, Panagiotou, Aikaterini, Armylagos, Stylianos, Rokas, Konstantinos, Gotzias, Dimitrios, Boulouta, Anna, Bozionelou, Vassiliki, Stravodimos, Konstantinos, Varkarakis, Ioannis, Mavroudis, Dimitrios, and Dimopoulos, Meletios-Athanasios

Published
2023
Full Text
View/download PDF

25. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 ‘CaboGIST’

Author

Kyriazoglou, Anastasios, primary, Jespers, Pieter, additional, Vandecavaye, Vincent, additional, Mir, Olivier, additional, Kasper, Bernd, additional, Papai, Zsuzsanna, additional, Blay, Jean-Yves, additional, Italiano, Antoine, additional, Zaffaroni, Facundo, additional, Litière, Saskia, additional, Nzokirantevye, Axelle, additional, and Schöffski, Patrick, additional

Published
2022
Full Text
View/download PDF

26. Tyrosine kinase inhibitors in sarcoma treatment (Review)

Author

Kyriazoglou, Anastasios, primary, Gkaralea, Lydia, additional, Kotsantis, Ioannis, additional, Anastasiou, Maria, additional, Pantazopoulos, Anastasios, additional, Prevezanou, Maria, additional, Chatzidakis, Ioannis, additional, Kavourakis, Georgios, additional, Economopoulou, Panagiota, additional, Nixon, Ioanna, additional, and Psyrri, Amanda, additional

Published
2022
Full Text
View/download PDF

27. Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Author

Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris and Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa and Bergamini, Cristiana Colombo, Elena Caspani, Francesca and Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo

Abstract

Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.

Published
2022

28. Chasing Hippos: Implications of YAP1 and TAZ Expression in Pregnancy-associated Breast Cancer Tumorigenesis

Author

KYRIAZOGLOU, ANASTASIOS, primary, KORAKITI, ANNA-MARIA, additional, PAPATHEODORIDI, ALKISTIS-MARIA, additional, APOSTOLIDOU, KLEONIKI, additional, NONNI, AFRODITI, additional, ZOGRAFOS, ELENI, additional, BLETSA, GARYFALIA, additional, TSAKOGIANNIS, DIMITRIS, additional, DIMOPOULOS, MELETIOS-ATHANASIOS, additional, and ZAGOURI, FLORA, additional

Published
2022
Full Text
View/download PDF

29. Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Author

Economopoulou, Panagiota, primary, Pantazopoulos, Anastasios, additional, Spathis, Aris, additional, Kotsantis, Ioannis, additional, Kyriazoglou, Anastasios, additional, Kavourakis, George, additional, Zakopoulou, Roubini, additional, Chatzidakis, Ioannis, additional, Anastasiou, Maria, additional, Prevezanou, Maria, additional, Resteghini, Carlo, additional, Licitra, Lisa, additional, Bergamini, Cristiana, additional, Colombo, Elena, additional, Caspani, Francesca, additional, Denaro, Nerina, additional, Vecchio, Stefania, additional, Bonomo, Pierluigi, additional, Cossu Rocca, Maria, additional, Bertolini, Federica, additional, Ferrari, Daris, additional, Psyrri, Amanda, additional, and Bossi, Paolo, additional

Published
2021
Full Text
View/download PDF

34. CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience

Author

Andrikopoulou, Angeliki, primary, Fiste, Oraianthi, additional, Apostolidou, Kleoniki, additional, Skafida, Efthymia, additional, Markellos, Christos, additional, Liontos, Michalis, additional, Kyriazoglou, Anastasios, additional, Dimopoulos, Meletios-Athanasios, additional, and Zagouri, Flora, additional

Published
2021
Full Text
View/download PDF

35. CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience

Author

Andrikopoulou, Angeliki Fiste, Oraianthi Apostolidou, Kleoniki Skafida, Efthymia Markellos, Christos Liontos, Michalis Kyriazoglou, Anastasios Dimopoulos, Meletios-Athanasios Zagouri, Flora

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2021

37. Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review

Author

Kyriazoglou, Anastasios Kaparelou, Maria Goumas, Georgios Liontos, Michael Zakopoulou, Roubini Zografos, Eleni Zygogianni, Anna Dimopoulos, Meletios Athanasios Zagouri, Flora

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2021

39. Systematic Review of Recurrent Osteosarcoma Systemic Therapy

Author

Gazouli, Ioanna, primary, Kyriazoglou, Anastasios, additional, Kotsantis, Ioannis, additional, Anastasiou, Maria, additional, Pantazopoulos, Anastasios, additional, Prevezanou, Maria, additional, Chatzidakis, Ioannis, additional, Kavourakis, Georgios, additional, Economopoulou, Panagiota, additional, Kontogeorgakos, Vasileios, additional, Papagelopoulos, Panayiotis, additional, and Psyrri, Amanda, additional

Published
2021
Full Text
View/download PDF

40. Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review

Author

Kyriazoglou, Anastasios, primary, Kaparelou, Maria, additional, Goumas, Georgios, additional, Liontos, Michael, additional, Zakopoulou, Roubini, additional, Zografos, Eleni, additional, Zygogianni, Anna, additional, Dimopoulos, Meletios Athanasios, additional, and Zagouri, Flora, additional

Published
2021
Full Text
View/download PDF

42. Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

Author

Kyriazoglou, Anastasios, Koutsoukos, Konstantinos, Zagouri, Flora, Liontos, Michalis, Dimitriadis, Efthimios, Tiniakos, Dina, and Dimopoulos, Meletios Athanasios

Subjects
1st line treatment, Therapeutics and Clinical Risk Management, Case Series, Olaratumab and Doxorubicin, metastatic hepatic epithelioid hemangioendothelioma
Abstract

Anastasios Kyriazoglou, 1 Konstantinos Koutsoukos, 1 Flora Zagouri, 1 Michalis Liontos, 1 Efthimios Dimitriadis, 2 Dina Tiniakos, 3, 4 Meletios Athanasios Dimopoulos 1 1Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece; 2Department of Genetics, Agios Savvas Hospital, Athens, Greece; 3Department of Pathology Aretaion Hospital, National & Kapodistrian University of Athens, Athens, Greece; 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UKCorrespondence: Anastasios Kyriazoglou Vasilisis Sofias 80, Athens 11528, GreeceTel +302132162545Fax +302132162511Email tassoskyr@gmail.comAbstract: Epithelioid hemangioendothelioma(EHE) is a rare vascular malignant tumor with indolent course. Liver transplantation for local disease is the treatment of choice. In the metastatic setting there is no consensus regarding the appropriate systemic treatment. We present two cases of metastatic hepatic epithelioid hemangioendothelioma(hEHE) treated with the combination of Doxorubicin and Olaratumab. Both patients showed Stable Disease(SD) as a response, after the completion of six cycles of this combination therapy.Keywords: Olaratumab and Doxorubicin, metastatic hepatic epithelioid hemangioendothelioma, 1st line treatment

Published
2020

48. Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

Author

Kyriazoglou,Anastasios, Koutsoukos,Konstantinos, Zagouri,Flora, Liontos,Michalis, Dimitriadis,Efthimios, Tiniakos,Dina, Dimopoulos,Meletios Athanasios, Kyriazoglou,Anastasios, Koutsoukos,Konstantinos, Zagouri,Flora, Liontos,Michalis, Dimitriadis,Efthimios, Tiniakos,Dina, and Dimopoulos,Meletios Athanasios

Abstract

Anastasios Kyriazoglou, 1 Konstantinos Koutsoukos, 1 Flora Zagouri, 1 Michalis Liontos, 1 Efthimios Dimitriadis, 2 Dina Tiniakos, 3, 4 Meletios Athanasios Dimopoulos 1 1Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece; 2Department of Genetics, Agios Savvas Hospital, Athens, Greece; 3Department of Pathology Aretaion Hospital, National & Kapodistrian University of Athens, Athens, Greece; 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UKCorrespondence: Anastasios Kyriazoglou Vasilisis Sofias 80, Athens 11528, GreeceTel +302132162545Fax +302132162511Email tassoskyr@gmail.comAbstract: Epithelioid hemangioendothelioma (EHE) is a rare vascular malignant tumor with indolent course. Liver transplantation for local disease is the treatment of choice. In the metastatic setting there is no consensus regarding the appropriate systemic treatment. We present two cases of metastatic hepatic epithelioid hemangioendothelioma (hEHE) treated with the combination of Doxorubicin and Olaratumab. Both patients showed Stable Disease (SD) as a response, after the completion of six cycles of this combination therapy.Keywords: Olaratumab and Doxorubicin, metastatic hepatic epithelioid hemangioendothelioma, 1st line treatment

Published
2020

50. Management of Synovial Sarcoma in a Tertiary Referral Center: A Retrospective Analysis of 134 Patients

Author

Kyriazoglou, Anastasios, primary, Timmermans, Iris, additional, De Cock, Lore, additional, Laenen, Annouschka, additional, Dumez, Herlinde, additional, Sinnaeve, Friedl, additional, Wafa, Hazem, additional, Hompes, Daphne, additional, Van Raemdonck, Dirk, additional, De Leyn, Paul, additional, Sciot, Raf, additional, Hauben, Esther, additional, Debiec-Rychter, Maria, additional, Vandenbempt, Isabelle, additional, and Schöffski, Patrick, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results